Curative effect of W+T treatment in vivo.

Slides:

Advertisements

Similar presentations

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

Advertisements

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Antitumor activity of BAY in patient-derived tumor models.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Effects of SC144 on in vivo ovarian tumor.

The STM1787 promoter in Salmonella is rapidly activated in vivo by the tumor microenvironment. The STM1787 promoter in Salmonella is rapidly activated.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

In vivo efficacy of gemcitabine and MK-1775.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

MI-773 reduces the fraction of CSCs and prevents recurrence in ACC xenograft tumors. MI-773 reduces the fraction of CSCs and prevents recurrence in ACC.

Activity of MAC-321 (i. v. and p. o

Effect of MI-773 dosing on long-term efficacy.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

PTENP1 sensitizes renal cancer cells to chemotherapy.

Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.

coTCRcys-transduced T cells control tumor growth in vivo.

Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

GA reduces the growth of Caki-1 tumor xenografts.

Antitumor effects of celastrol in vitro and in vivo.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Xenograft regrowth studies.

ERK reactivation following EGFR TKI treatment.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

CRA inhibits the growth of human tumor xenografts in vivo.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

HMQ1611 inhibited breast tumor growth in mice.

Effect of CDV on human SF7796 xenografts in vivo.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Possible outcomes of therapeutic treatments using the spiral model.

Comparative effect of anti-TIM3 against experimental tumors.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.

TAE-684 effectively inhibits the growth of H3122 in vivo.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

PDL192 and inhibit the growth of xenograft tumors.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Heterogeneous resistance mechanisms develop in response to W+T combination treatment in the EGFRL858R/T790M genetically engineered mice. Heterogeneous.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

Ceritinib is a potent ALK inhibitor in crizotinib-naïve models.

PLK1 is a crucial downstream effector of PDK1 for MYC activation and cell survival. PLK1 is a crucial downstream effector of PDK1 for MYC activation and.

In vivo effect of KIN-193 on PTEN-deficient tumors.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

Presentation transcript:

Curative effect of W+T treatment in vivo. Curative effect of W+T treatment in vivo. A, PC9 GR4 xenograft tumors were treated with vehicle control, WZ4002, trametinib (tram), or the combination thereof (mean ± SEM, 5 mice per condition). Treatment cessation is indicated by the arrow. Tumor cure is defined as no residual disease beyond treatment cessation. B, W+T treatment is also effective in the TKI-naïve PC9 xenograft model (mean ± SEM, n = 5). C, W+T treatment prevents tumor growth in the H1975 xenograft model but does not result in tumor cures (mean ± SEM, n = 5). Erin M. Tricker et al. Cancer Discovery 2015;5:960-971 ©2015 by American Association for Cancer Research